- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00133835
Comparison of ESWL Alone and ESWL + Endoscopy for Painful Chronic Pancreatitis
Comparison of ESWL Alone and ESWL Combined With Endoscopic Drainage of the Main Pancreatic Duct for Painful Chronic Pancreatitis
Study Overview
Status
Conditions
Detailed Description
Endoscopic drainage of the main pancreatic duct is an established method of treatment of painful obstructive calcified chronic pancreatitis (CP). It involves disintegration of calcifications using extracorporeal shock wave lithotripsy (ESWL) followed by endoscopic removal of stone fragments, possibly associated with stent insertion. A pilot study suggests that ESWL alone in calcified CP is followed by spontaneous elimination of stone fragments and pain relief, without sphincterotomy. After ESWL alone, the exocrine function was found to return to normal values in some cases. Potential benefits include lower costs and morbidity as well as wider availability compared to endoscopic techniques.
The primary outcome of this randomized controlled trial is to compare the relapse of pain at 2 years after treatment with ESWL alone or endoscopic treatment, consisting of ESWL followed by endoscopic stone extraction. Secondary outcomes include a comparison of technical results (as assessed by abdominal CT Scan 1 week after the last intervention and secretin-enhanced magnetic resonance at 1 month), complication rates, and treatment-related costs in both groups.
Patients are eligible to participate in the study according to the following criteria:
Inclusion criteria :
- painful chronic pancreatitis (abdominal pain attack during the preceding 12 months);
- at least 1 calcified stone greater than 4 mm in one of its axes in the cephalic or corporeal portion of the main pancreatic duct with upstream duct dilation;
- written informed consent obtained from the patient.
Exclusion criteria:
- history of treatment of the pancreas using ESWL, endoscopy, or surgery;
- pancreatic collection greater than 2 cm in diameter at magnetic resonance or CT Scan;
- alkaline phosphatase levels greater than twice the upper limit of normal values or signs of cholangitis;
- age below 18 years;
- pregnancy or lactation.
Pretherapeutic work-up will include detailed medical history (including date of the first episode of typical abdominal pain, date of diagnosis of CP, number of episodes of pain during the last year, alcohol intake, pain continuous or intermittent during the last episode, medication, intensity of the last episode of pain on a 10-point scale as previously described), blood chemistry, stool sampling (for elastase measurement), triolein breath test, plain abdominal film taken in four classical positions (left anterior oblique, right anterior oblique, lateral, and supine), CT Scan without contrast medium injection, and secretin-enhanced magnetic resonance cholangiopancreatography (S-MRCP).
After informed consent of the referring physician has been obtained, patients will be asked to participate in the study. If the patient accepts, after oral and written consent, he (or she) will be randomized to the ESWL or endoscopy group by opening an opaque sealed envelope numbered according to a table of random numbers.
ESWL will be performed in all patients using a electromagnetic lithotriptor as previously described. Shock-waves will be focused on the obstructing stones (if multiple stones are present, those responsible for MPD obstruction will be identified by comparing plain abdominal film, CT Scan and S-MRCP). ESWL sessions will be repeated if necessary, until stone fragmentation is obtained, as confirmed by abdominal plain film centered on the targeted area of the pancreas. At this time, treatment will be considered terminated in the ESWL group, patients in the endoscopy group will undergo endoscopy immediately, for endoscopic extraction of stone fragments possibly associated to stent insertion according to previously published criteria and techniques.
Cross-over: in the ESWL group, if no elimination of the fragments is observed one week after the last ESWL, endoscopic drainage of the main pancreatic duct will be carried out at this time in case of continuous pain. For patients without continuous pain, delayed spontaneous elimination of the fragments will be sought by CT Scan and S-MRCP 2 months after the last ESWL. Endoscopic drainage of the main pancreatic duct will be proposed during follow-up only to the patients presenting a painful attack of CP.
Follow-up will consist of clinical examination 1 month after treatment and every 6 months thereafter. Data collected will include pain relapses, ESWL, endoscopic and surgical procedures, weight change, plus any other seemingly unrelated medical treatments. In addition to this, a S-MRCP will be performed 1 month after treatment. Triolein breath test will be performed at 1 month and 1 year. Sampling of stools (for elastase measurement) will be obtained every year.
Costs will be calculated starting on the day of first treatment as previously described. Costs not directly related to the treatment of pain or of procedure-related complications (e.g., diabetes) will be disregarded.
Study Type
Enrollment
Phase
- Phase 2
- Phase 1
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Painful chronic pancreatitis (>1 abdominal pain attack during the preceding 12 months)
- At least 1 calcified stone greater than 4 mm in one of its axes in the cephalic or corporeal portion of the main pancreatic duct (MPD) with upstream duct dilation
- Written informed consent obtained from the patient
Exclusion Criteria:
- History of treatment of the pancreas using ESWL, endoscopy, or surgery
- Pancreatic collection greater than 2 cm in diameter at magnetic resonance or CT scan
- Alkaline phosphatase levels greater than twice the upper limit of normal values or signs of cholangitis
- Age below 18 years
- Pregnancy or lactation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Relapse of pain at 2 years
|
Secondary Outcome Measures
Outcome Measure |
---|
Diameter of the main pancreatic duct at 1 month
|
Complication rate at 1 month
|
Treatment-related costs of initial intervention and during follow-up
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jean-Marc Dumonceau, University Hospital, Geneva
- Principal Investigator: Jacques Devière, Erasme University Hospital
- Principal Investigator: Guido Costamagna, Catholic University of Roma
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 97.187
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatitis
-
Changhai HospitalUnknownChronic Pancreatitis | Idiopathic Chronic PancreatitisChina
-
Centre Hospitalier Universitaire de NiceRecruiting
-
Tianjin Nankai HospitalCompletedAcute PancreatitisChina
-
Copenhagen University Hospital, HvidovreRecruitingFibrosis | Inflammation | Pancreatitis | Chronic Pancreatitis | Acute Pancreatitis | Recurrent PancreatitisDenmark
-
Massachusetts General HospitalTerminatedChronic Pancreatitis | Acute Recurrent PancreatitisUnited States
-
Changhai HospitalEnrolling by invitationChronic Pancreatitis | Acute Pancreatitis | Healthy PeopleChina
-
Postgraduate Institute of Medical Education and...Completed
-
Dartmouth-Hitchcock Medical CenterCompleted
-
The Cleveland ClinicChiRhoClin, Inc.; The National Pancreas FoundationCompletedChronic PancreatitisUnited States
Clinical Trials on Extracorporeal shock wave lithotripsy
-
Sohag UniversityCompletedDetermine the Efficacy and Safety of SWL in Renal Stones Larger Than 2 cm in Pediatric Age GroupEgypt
-
Chinese University of Hong KongWithdrawnHypertension | Renal StoneHong Kong
-
Washington University School of MedicineTerminatedUrolithiasisUnited States
-
Changhai HospitalRecruitingPancreatic Duct StoneChina
-
University of Colorado, DenverEnrolling by invitationPancreatitis, ChronicUnited States
-
Ain Shams UniversityScience,Technology & Innovation Funding AuthorityRecruitingAcute Kidney Injury | Renal Calculi | Percutaneous Nephrolithotomy | Extracorporeal Shockwave LithotripsyEgypt
-
Imam Abdulrahman Bin Faisal UniversityCompleted
-
Mansoura UniversityUnknown
-
EgymedicalpediaCompletedStone, Kidney | Child, OnlyEgypt